UK chain pulls analgesic promotion
This article was originally published in The Tan Sheet
Executive Summary
Tesco for the second time withdraws a volume-based promotional offer for analgesics after a competitor, Alliance Boots, complains the promotion violates restrictions on retail pack sizes, the Medicines & Healthcare products Regulatory Agency (MHRA) announces Oct. 4. Tesco offered a "two for one" promotion for Wrafton Laboratories' Resolve and Resolve Extra acetaminophen products, according to the MHRA release. However, Alliance Boots told MRHA the promotion exceeds the guideline on restricting consumers' purchases of analgesics that UK retailers have agreed to follow. The British retailer withdrew a similar promotion in June 2005 (1The Tan Sheet" June 27, 2005, In Brief). The health authority reached agreements with several other retailers, according to the release...
You may also be interested in...
MHRA analgesic marketing
Volume-based painkiller promotions have been withdrawn by British retailers Tesco and Superdrug following two complaints upheld by the Medicines & Healthcare products Regulatory Agency, the health agency announces June 14. MHRA notes promotional offers such as "two for the price of one" and "buy one, get one free" undermine the government's limits on analgesic pack sizes, referencing a 2004 British Medical Journal study which linked reductions in suicides and liver toxicity to size restrictions (1"The Tan Sheet" Nov. 8, 2004, p. 9). The government "will consider changing the law if retailers do not act responsibly," MHRA Policy Group Manager Jeremy Mean notes...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.